Last updated 2026-06-18
- Raised $45M funding round, Feb 2020
- Raised $8.8M funding round, Dec 2017
- Raised $9.2M funding round, Oct 2016
Total raised
$65.5M
Last: 2020-02
Stage
Series C
Founded
2015
Headcount
15
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful yet safe native antibacterial immune reaction. The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
Funding history · 4 rounds · $65.5M total
2020-02
2017-12
$8.8M
2016-10
$9.2M
2015-12
Undisclosed
Q&A
- What is NeoTX's primary focus?
- NeoTX is focused on immuno-oncology drug development, leveraging its proprietary Selective T cell Redirection (STR) platform to create targeted anticancer immunotherapies.
- What is the current development stage of NeoTX's lead molecule?
- NeoTX's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
- When was NeoTX founded?
- NeoTX was founded in April 2015.
- What is NeoTX's total funding to date?
- NeoTX has raised a total of $65.5 million USD.
- When was NeoTX's most recent funding round and how much was raised?
- NeoTX's most recent funding round occurred in February 2020, raising $45 million USD.
- Which investors participated in NeoTX's February 2020 funding round?
- The February 2020 funding round included J. Tomilson Hil and Maurice Greenberg.
- What is NeoTX's current funding stage?
- NeoTX is currently in its Series C funding stage.
- Where is NeoTX headquartered?
- NeoTX is headquartered in Rehovot, Israel.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
drug-developmentdrug-discoverybiopharmaceuticalcancer-therapyoncologycancertherapeuticsimmunotherapycell-therapypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neotx.com/ |
|---|---|
| linkedin.com/company/27245756 | |
| Wikipedia | he.wikipedia.org/wiki/%D7%A0%D7%90%D7%95%D7%98%D7%A7%D7%A1 |
| Wikidata | wikidata.org/wiki/Q137781710 |
Identifiers & details
| Founded | 2015-4 |
|---|---|
| Employees (exact) | 15 |
| Wikidata QID | Q137781710 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Publications (Crossref)
| Works | 9 |
|---|
Web history (Wayback)
| Domain | neotx.com |
|---|
Wikidata
| QID | Q137781710 |
|---|
Certificate / subdomain footprint
| Subdomains | 21 |
|---|